GCT BD team has been enriched and we are happy to announce that Chris Matheus joined us to enhance GCT brand recognition as a global clinical CRO.
“I know Chris for several years now and it is to my great pleasure to welcome him to GCT Team. His expertise is very much valued and professional attitude is fully aligned with ours, therefore, we look forward to working together building new successful relationships within the industry,” comments Dr. Eugene Selivra, Chief Executive Officer of GCT.”
Updated: June 22nd, 2018
GCT has worked closely with the Sponsor on reaching this important milestone and over the past months has secured Regulatory and EC approvals, conducted site initiation visits and managed shipments of required supplies to the sites. We have successfully progressed to the enrollment start on schedule in the two participating countries – Hungary and Poland.
Updated: June 4th, 2018
GCT is delighted to announce that the approval for an international double-blind Phase III cardiac surgery study was granted by the Russian Ministry of Health.
We manage the Russian part of the clinical trial that will be performed by a dedicated team of Investigators at the leading Cardiology Institute. Our team is responsible for regulatory, clinical and drug logistics services.
Updated: May 17th, 2018
GCT study team is proud to announce a huge milestone achievement – the last study subject has been randomized in multinational Phase III clinical study in patients with a previous preterm delivery – the largest obstetrics/gynecology study conducted so far.
Updated: April 5th, 2018
GCT is already managing 5 multicentre clinical trials in Hungary and GCT team is set up for further expansion.
The steady growth has made it necessary to relocate GCT team in Budapest to a larger office.
Updated: March 16th, 2018
Close-out visits are scheduled to be performed by GCT team in Russia for a Phase III multi-center double-blind anaesthesiology study sponsored by a leading Russian pharmaceutical company. (more…)
Updated: March 16th, 2018
A multi-center phase-II study is currently ongoing in 5 countries. Last week GCT was awarded a contract to expand the study and include 2 additional sites in Ukraine.
At the moment our Ukrainian office has already submitted study documents to Regulatory Authority. (more…)
Updated: March 2nd, 2018
An innovative medical device company appointed GCT to perform clinical trials for the state registration of a non-invasive device for coronary stents. GCT is proud to be a part of the team which will bring this cutting-edge technology on the market. For the successful conduct of clinical trial in the future we are initially providing Sponsor with the vital segment of clinical research – medical writing services. (more…)
Updated: March 2nd, 2018
Growing steadily, GCT has extended its network and strong coverage of the EE region by establishing clinical operations in the Republic of Moldova.
We now offer full support for clinical trials in Moldova, including feasibility, clinical monitoring, project and site management, and regulatory services.
Updated: February 14th, 2018
Updated: February 7th, 2018
Updated: January 31st, 2018
GCT is proud to be conducting the extensive international Phase III clinical study in women’s health. Our full-time in-house teams are responsible for the enrollment of over 1,000 patients in CEE region including Ukraine, Russia, Hungary, Czech Republic and Bulgaria. (more…)
Updated: January 22nd, 2018
We are proud to announce that Global Clinical Trials (GCT) has gained EC and RA approval last week in Hungary for the ongoing ophthalmology project. This approval allows GCT to continue to demonstrate its well-established knowledge and experience in conducting clinical trials across various ophthalmic indications. The clinical sites in Hungary are part of a large multinational, phase II diabetic macular edema clinical study being conducted within the European Union. (more…)
Updated: January 9th, 2018
Today Vladimir Seredyuk, MD, Quality Assurance Director conducted internal on-site audit of GCT warehousing facility in Saint-Petersburg, Russia. We are happy to announce that no major findings were revealed. (more…)
Updated: December 26th, 2017
As the year draws to a close, GCT team would like to take the opportunity to thank you, loyal supporters, for your continued dedication to experiencing the real difference with our high-quality clinical trials. GCT continues to expand in 2017 and has currently local offices across 10 countries in Central and Eastern Europe, Russia and India.
We always listen and appreciate your feedback and will certainly implement all the comments you made, as we believe that there is always a room for improvement.
Updated: December 21st, 2017
Dr. Tothova has joined the GCT team this September as a Senior CRA based out of our Hungarian office. Margita is a Medical Doctor with over a decade of experience in the clinical trials industry. After graduation from the Comenius University of Bratislava Margita started her medical career from working as a pediatrist at the General Hospital of Komarno. A few years later she joined one of the biggest pharmaceutical companies as their local representative. Once Dr. Tothova entered the world of clinical trials, she continued to gain valuable experience and soon became a countries lead for Slovakia, Hungary and Czech Republic.
Updated: November 30th, 2017
We are proud to announce that GCT was selected as the contractor by the Polish Pharma company in connection with their participation in the Operational Program Intelligent Development 2014-2020, which is organized by the National Center for Research and Development in Poland.
During the tender, GCT has gained the highest score based on the strict selection criteria. It is always a goal for us to meet the requirements of our Sponsors and we look forward to start yet another successful collaboration.
A randomized multicenter controlled Phase IIa clinical trial on a novel pharmaceutical topical gel for wound healing will be performed by GCT in several European countries with participation of 15 clinical sites. (more…)
Updated: November 13th, 2017
We are delighted to announce that both EC and RA approvals to conduct clinical trial in Benign Prostatic Hyperplasia patients were received by GCT team earlier this week. We are preparing for the site initiation in order to start screening and enrollment procedures in November.
Benign Prostatic Hyperplasia is the non-cancerous enlargement of the prostate, affecting about 50% of men above 60 years of age and more than 70% of men ages 70 and above. Please contact us at email@example.com to navigate through the clinical, regulatory and logistical aspects of conducting device and pharmaceutical trials in Slovakia and other EU countries. (more…)
Updated: October 26th, 2017
In September GCT was awarded a program of wAMD in Europe. Two studies will be conducted to investigate therapeutic effects and safety of a treatment regimen in patients with wet form of Age-related macular degeneration.
Updated: October 20th, 2017